Hemant Surgical Buys Majority Stake in Cancer Research Firm

Hemant Surgical Industries will acquire 66.66% of Lifesenz Cancer Research Labs for ₹19.998 crore.

Key Takeaway: Hemant Surgical is expanding into cancer diagnostics, acquiring a firm that is currently losing money and has a negative net worth.

What Happened

Hemant Surgical Industries Limited has agreed to purchase a 66.66% equity stake in Lifesenz Cancer Research Labs Private Limited. The deal is for ₹19.998 crore, to be paid in cash. Lifesenz Cancer Research Labs will become a subsidiary of Hemant Surgical Industries once the acquisition is complete.

Why It Matters

This acquisition is a strategic step for Hemant Surgical Industries to grow its presence in the healthcare sector, especially in cancer diagnostic support. Lifesenz Cancer Research Labs offers predicted therapy solutions, which fits with the increasing need for advanced cancer care.

The Background

Lifesenz Cancer Research Labs Private Limited was established in February 2022. For the financial year 2024-25, it reported a turnover of ₹0.5675 crore, a net loss of ₹0.7476 crore, and a negative net worth of ₹2.2184 crore.

What Changes Next

Once the deal closes, Lifesenz Cancer Research Labs will operate as a subsidiary. Its predicted therapy solutions will be integrated into Hemant Surgical Industries' wider healthcare services. The acquisition is expected to be completed by September 30, 2026.

Potential Risks

Investors should be aware that Lifesenz Cancer Research Labs is currently unprofitable and has a negative net worth. This could affect Hemant Surgical Industries' combined financial results in the near term. Since this is a transaction between related parties, the valuation and its fairness require careful review.

Key Metrics

• Acquisition Cost: ₹19.998 crore
• Target Turnover (FY 24-25): ₹0.5675 crore
• Target Net Loss (FY 24-25): ₹0.7476 crore
• Target Net Worth (FY 24-25): Negative ₹2.2184 crore
• Deal Completion Deadline: September 30, 2026

What to Watch

Shareholders should track the progress of the acquisition's completion by the September 30, 2026 deadline. They should also look for updates on how Lifesenz Cancer Research Labs' operations are integrated and how they affect Hemant Surgical Industries' financial performance, especially given the target company's current financial situation.